Latest:
Common Patient Questions About Insulin Biosimilars Pertain to Classification
Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Authors
Ted Mathias, JD
Ted Mathias focuses on trying patent cases. In the last 2 years, he tried 2 cases to judgment and served as lead counsel in a case involving 33 patents that settled favorably on the eve of trial. Mathias has litigated patent cases and handled successful appeals to the Federal Circuit in the areas of medical devices, pharmaceuticals, mechanical devices, e-commerce and software.
Latest:
Opinion: Purple Book Patent Listings Are Only a First Step
Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Mayuri Mathuria, MBA
Mayuri Mathuria, MBA, is a consultant in
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Brooke McCormick
Brooke McCormick is an assistant editor for
Latest:
Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars
Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.
Rose McNulty
Rose McNulty is a Managing Editor for
Latest:
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.
Jessica Mourani, PharmD
Jessica Mourani, PharmD, is Director of Clinical Outcomes for CPS Solutions.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Lindsey Mulrooney
Latest:
Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections
Julie M. Reed, the executive director of the Biosimilars Forum, dives into the efforts that the Forum is taking to ensure that FDA can catch up on their inspections backlog and get biosimilar approvals back on track.
Denise Myshko
Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com
Latest:
CVS Caremark Switches Up Biosimilar Coverage in 2024
As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Advertisement
Advertisement